GlassScriptPhysician profile
Patris Almasi
NPI 1336501659
$5,509.56
in general payments reported to CMS, 2019-2025
16 companies · $603 in 2025
The $603 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $161 · 2022: $3,185 · 2023: $602 · 2024: $959 · 2025: $603.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,164.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,163.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $2,230.63 | 2022-2025 | Proclaim |
| Boston Scientific Corporation | $712.64 | 2022-2025 | General - Pain Management, Wavewriter Alpha Prime 16 |
| Collegium Pharmaceutical, INC. | $577.37 | 2022-2025 | Belbuca, Xtampza |
| Nevro Corp. | $577.18 | 2021-2024 | Senza |
| Medtronic, INC. | $417.53 | 2022-2025 | Intellis Adaptivestim, Inceptiv |
| Avanos Medical | $205.53 | 2023-2025 | Coolief* Cooled Radiofrequency, Standard Rf Disposables, Coolief Cooled Radiofrequency |
| Averitas Pharma INC. | $164.60 | 2024-2025 | Qutenza |
| Spr Therapeutics, INC | $150.07 | 2023-2025 | Sprint Pns System |
| Abbvie INC. | $132.75 | 2022-2025 | Botox |
| Acelrx Pharmaceuticals, INC. | $109.83 | 2021 | |
| Vertex Pharmaceuticals Incorporated | $85.01 | 2024-2025 | |
| Ibsa Pharma INC. | $56.76 | 2022-2023 | Tirosint, Licart |
| Stryker Corporation | $32.09 | 2022 | |
| Merz Pharmaceuticals, LLC | $22.13 | 2024 | Xeomin |
| Forte Bio-Pharma LLC | $19.80 | 2024 | Prolate, Nalocet |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Valinor Pharma, LLC | $15.64 | 2025 | Movantik |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patris Almasi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.